Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Front Immunol ; 13: 921488, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35874732

RESUMEN

The angiotensin AT2 receptor (AT2R) is a main receptor of the protective arm of the renin-angiotensin system and exerts for instance anti-inflammatory effects. The impact of AT2R stimulation on autoimmune diseases such as rheumatoid arthritis (RA) is not yet known. We investigated the therapeutic potential of AT2R-stimulation with the selective non-peptide AT2R agonist Compound 21 (C21) in collagen-induced arthritis (CIA), an animal model for inflammatory arthritis. Arthritis was induced by immunization of DBA/1J mice with collagen type II (CII). Prophylactic and therapeutic C21 treatment alleviates arthritis severity and incidence in CIA. Joint histology revealed significantly less infiltrates of IL-1 beta and IL-17A expressing cells and a well-preserved articular cartilage in C21- treated mice. In CIA, the number of CD4+CD25+FoxP3+ regulatory T (Treg) cells significantly increased upon C21 treatment compared to vehicle. T cell differentiation experiments demonstrated increased expression of FoxP3 mRNA, whereas IL-17A, STAT3 and IFN-gamma mRNA expression were reduced upon C21 treatment. In accordance with the mRNA data, C21 upregulated the percentage of CD4+FoxP3+ cells in Treg polarizing cultures compared to medium-treated controls, whereas the percentage of CD4+IL-17A+ and CD4+IFN-gamma+ T cells was suppressed. To conclude, C21 exerts beneficial effects on T cell-mediated experimental arthritis. We found that C21-induced AT2R-stimulation promotes the expansion of CD4+ regulatory T cells and suppresses IL-17A production. Thus, AT2R-stimulation may represent an attractive treatment strategy for arthritis.


Asunto(s)
Artritis Experimental , Receptor de Angiotensina Tipo 2 , Linfocitos T Reguladores , Animales , Artritis Experimental/inducido químicamente , Artritis Experimental/tratamiento farmacológico , Factores de Transcripción Forkhead/metabolismo , Imidazoles , Interleucina-17/metabolismo , Ratones , Ratones Endogámicos DBA , ARN Mensajero/metabolismo , Receptor de Angiotensina Tipo 2/metabolismo , Sulfonamidas , Linfocitos T Reguladores/inmunología , Tiofenos , Regulación hacia Arriba
2.
Int J Mol Sci ; 22(24)2021 Dec 20.
Artículo en Inglés | MEDLINE | ID: mdl-34948475

RESUMEN

Compound 21 (C21), an AT2 receptor agonist, and Angiotensin 1-7 (Ang 1-7), through Mas receptor, play an important role in the modulation of the protective arm of the renin-angiotensin system. The aim of this study was to investigate in an experimental model of angiotensin II-dependent hypertension whether the activation of the potentially protective arm of the renin-angiotensin system, through AT2 or Mas receptor stimulation, counteracts the onset of myocardial fibrosis and hypertrophy, and whether these effects are mediated by inflammatory mechanism and/or sympathetic activation. Sprague Dawley rats (n = 67) were treated for 1 (n = 25) and 4 (n = 42) weeks and divided in the following groups: (a) Angiotensin II (Ang II, 200 ng/kg/min, osmotic minipumps, sub cutis); (b) Ang II+Compound 21 (C21, 0.3 mg/kg/day, intraperitoneal); (c) Ang II+Ang 1-7 (576 µg/kg/day, intraperitoneal); (d) Ang II+Losartan (50 mg/kg/day, per os); (e) control group (physiological saline, sub cutis). Systolic blood pressure was measured by tail cuff method and, at the end of the experimental period, the rats were euthanized and the heart was excised to evaluate myocardial fibrosis, hypertrophy, inflammatory cell infiltration and tyrosine hydroxylase expression, used as marker of sympathetic activity. Ang II caused a significant increase of blood pressure, myocardial interstitial and perivascular fibrosis and myocardial hypertrophy, as compared to control groups. C21 or Ang 1-7 administration did not modify the increase in blood pressure in Ang II treated rats, but both prevented the development of myocardial fibrosis and hypertrophy. Treatment with losartan blocked the onset of hypertension and myocardial fibrosis and hypertrophy in Ang II treated rats. Activation of AT2 receptors or Mas receptors prevents the onset of myocardial fibrosis and hypertrophy in Ang II-dependent hypertension through the reduction of myocardial inflammatory cell infiltration and tyrosine hydroxylase expression. Unlike what happens in case of treatment with losartan, the antifibrotic and antihypertrophic effects that follow the activation of the AT2 or Mas receptors are independent on the modulation of blood pressure.


Asunto(s)
Angiotensina II/administración & dosificación , Angiotensina I/administración & dosificación , Cardiomegalia/prevención & control , Hipertensión/tratamiento farmacológico , Imidazoles/administración & dosificación , Losartán/administración & dosificación , Fragmentos de Péptidos/administración & dosificación , Sulfonamidas/administración & dosificación , Tiofenos/administración & dosificación , Angiotensina I/farmacología , Angiotensina II/farmacología , Animales , Cardiomegalia/metabolismo , Modelos Animales de Enfermedad , Fibrosis , Hipertensión/inducido químicamente , Hipertensión/metabolismo , Imidazoles/farmacología , Inyecciones Intraperitoneales , Losartán/farmacología , Masculino , Fragmentos de Péptidos/farmacología , Proto-Oncogenes Mas/metabolismo , Ratas , Ratas Sprague-Dawley , Sulfonamidas/farmacología , Tiofenos/farmacología , Tirosina 3-Monooxigenasa/metabolismo
3.
Clin Sci (Lond) ; 134(7): 871-884, 2020 04 17.
Artículo en Inglés | MEDLINE | ID: mdl-32202299

RESUMEN

Recently, we designed a group of peptides by sequential substitution of the naturally occurring α-amino acid throughout the Ang III peptide sequence with the corresponding ß-amino acid. ß-Amino acid substitution at the proline residue of Ang III (ß-Pro7-Ang III) resulted in a highly selective AT2R ligand, demonstrating remarkable selectivity for the AT2R in both binding and functional studies. To provide additional functional evidence for the suitability of ß-Pro7 Ang III as a novel AT2R agonist, we tested effects of acute systemic administration of ß-Pro7-Ang III on renal hemodynamic and excretory function in anesthetized normotensive male and female rats. We also compared the natriuretic effects of acute intrarenal administration of native Ang III and ß-Pro7-Ang III in the presence of systemic AT1R blockade in anesthetized female rats to allow for the differentiation of systemic versus direct intrarenal natriuretic actions of ß-Pro7-Ang III. In both male and female rats, acute systemic administration of ß-Pro7-Ang III elicited renal vasodilatation and natriuresis. Notably, greater renal vasodilatory effects were observed in female versus male rats at the highest dose of ß-Pro7-Ang III administered. Moreover, intra-renal administration of ß-Pro7-Ang III produced significant natriuretic effects in female rats and, like Ang III, evoked AT2R translocation to the apical plasma membrane in renal proximal tubular cells. Taken together, our findings support the use of ß-Pro7-Ang III as a novel AT2R agonist and experimental tool for exploring AT2R function and its potential as a therapeutic target. Furthermore, our findings provide further evidence of a sex-specific influence of AT2R stimulation on renal function.


Asunto(s)
Angiotensina III/análogos & derivados , Riñón/irrigación sanguínea , Riñón/efectos de los fármacos , Natriuresis/efectos de los fármacos , Receptor de Angiotensina Tipo 2/agonistas , Circulación Renal/efectos de los fármacos , Sistema Renina-Angiotensina/efectos de los fármacos , Vasodilatación/efectos de los fármacos , Angiotensina III/farmacología , Animales , Femenino , Riñón/metabolismo , Masculino , Ratas Sprague-Dawley , Receptor de Angiotensina Tipo 2/metabolismo , Factores Sexuales , Transducción de Señal
4.
Exp Eye Res ; 186: 107680, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31129252

RESUMEN

The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in the regulation of blood pressure and body fluid homeostasis and is a mainstay for the treatment of cardiovascular and renal diseases. Angiotensin II and aldosterone are the two most powerful biologically active products of the RAAS, inducing all of the classical actions of the RAAS including vasoconstriction, sodium retention, tissue remodeling and pro-inflammatory and pro-fibrotic effects. In recent years, new components of the RAAS have been discovered beyond the classical pathway that have led to the identification of depressor or so-called protective RAAS pathways and the development of novel therapies targeting this system. Moreover, dual inhibitors which block the RAAS and other systems involved in the regulation of blood pressure or targeting upstream of angiotensin II by selectively deleting liver-derived angiotensinogen, the precursor to all angiotensins, may provide superior treatment for cardiovascular and renal diseases and revolutionize RAAS-targeting therapy.


Asunto(s)
Sistema Renina-Angiotensina/efectos de los fármacos , Sistema Renina-Angiotensina/fisiología , Bloqueadores del Receptor Tipo 1 de Angiotensina II/farmacología , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Angiotensinógeno/genética , Presión Sanguínea/fisiología , Líquidos Corporales/fisiología , Inhibidores Enzimáticos/farmacología , Homeostasis/fisiología , Humanos , Neprilisina/antagonistas & inhibidores , Oligopéptidos/farmacología , ARN Interferente Pequeño/farmacología , Receptor de Angiotensina Tipo 2/agonistas
5.
Curr Protein Pept Sci ; 18(8): 809-818, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28164758

RESUMEN

In 2004, the first nonpeptide selective angiotensin II type 2 receptor (AT2R) agonist was reported. This nonpeptide (C21), which, exerts anti-inflammatory and antifibrotic actions in vivo, has been extensively explored and is currently in clinical trials. Subsequently, a large number of related drug-like AT2R agonists have been disclosed. Reviews that summarize known structure-activity relationships (SAR) of nonpeptide AT2R agonists have recently appeared in the literature; however, very few reviews discuss the role of angiotensin peptides as AT2R agonists. Furthermore, to date, there have been no reports focusing on the medicinal chemistry perspective of peptide AT2R agonists. In the present review, reports on linear and conformationally constrained Ang II analogues, with a focus on AT2R selective ligands that are proven to act as agonists at the AT2 receptor are summarized. The impact of truncations and macrocyclizations of Ang II analogues and of incorporation of scaffolds that mimic secondary structures into Ang II related peptides is highlighted. A survey of the efforts to transform the nonselective octapeptide Ang II to more drug-like selective AT2R agonists is presented. The relationship between the structures of the AT2R agonists and their affinity to the AT2R is briefly discussed and common pharmacophore elements of AT2R selective Ang II peptide analogues and selective nonpeptide AT2R agonists are compared.


Asunto(s)
Angiotensina II/análogos & derivados , Antiinflamatorios/química , Antihipertensivos/química , Péptidos/química , Receptor de Angiotensina Tipo 2/agonistas , Sulfonamidas/química , Tiofenos/química , Angiotensina II/síntesis química , Angiotensina II/farmacología , Animales , Antiinflamatorios/síntesis química , Antiinflamatorios/farmacología , Antihipertensivos/síntesis química , Antihipertensivos/farmacología , Expresión Génica , Humanos , Hipertensión/tratamiento farmacológico , Hipertensión/genética , Hipertensión/metabolismo , Hipertensión/fisiopatología , Inflamación , Cinética , Péptidos/síntesis química , Péptidos/farmacología , Peptidomiméticos/síntesis química , Peptidomiméticos/química , Peptidomiméticos/farmacología , Receptor de Angiotensina Tipo 2/genética , Receptor de Angiotensina Tipo 2/metabolismo , Relación Estructura-Actividad , Sulfonamidas/síntesis química , Sulfonamidas/farmacología , Tiofenos/síntesis química , Tiofenos/farmacología
6.
ACS Med Chem Lett ; 5(10): 1129-32, 2014 Oct 09.
Artículo en Inglés | MEDLINE | ID: mdl-25313325

RESUMEN

Saralasin and sarile, extensively studied over the past 40 years as angiotensin II (Ang II) receptor blockers, induce neurite outgrowth in a NG108-15 cell assay to a similar extent as the endogenous Ang II. In their undifferentiated state, these cells express mainly the AT2 receptor. The neurite outgrowth was inhibited by preincubation with the AT2 receptor selective antagonist PD 123,319, which suggests that the observed outgrowth was mediated by the AT2 receptor. Neither saralasin nor sarile reduced the neurite outgrowth induced by Ang II proving that the two octapeptides do not act as antagonists at the AT2 receptor and may be considered as AT2 receptor agonists.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA